U.S. Stem Cell, Inc.: USRM Oral Argument in Appeal from FDA Enforcement Action
SUNRISE, FL / ACCESSWIRE / January 19, 2021 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments in the case United States v. U.S. Stem Cell Clinic, LLC, et al., took place on January 13, 2021, before the federal Eleventh Circuit Court of Appeals. The oral argument was held on the Company s appeal of a judgment denying it the right to present evidence and testimony in support of its position and practices in a trial. The Company continues to maintain it should be afforded the opportunity to support its position in such a trial.
USRM Oral Argument in Appeal from FDA Enforcement Action saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
A Florida clinic urged the Eleventh Circuit on Wednesday to throw out a ruling barring it from offering a stem cell procedure to treat various illnesses, arguing that a lower court erred in finding that the treatment is a drug subject to U.S. Food and Drug Administration regulations.